Stock Events

Stock Events

Vaxil Bio 

$0.11
3
+$0.01+4.76% Tuesday 18:49

Statistics

Day High
0.11
Day Low
0.11
52W High
1.75
52W Low
0
Volume
5,500
Avg. Volume
1,089
Mkt Cap
301,290
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

30SepExpected
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Q2 2021
-0
-0
-0
-0
Expected EPS
N/A
Actual EPS
-0.0014

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-253,990.06Net Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VXLLF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novavax
NVAX
Mkt Cap1.36B
Novavax is a competitor because it also focuses on developing vaccines for infectious diseases, similar to Vaxil Bio's focus on immunotherapy and vaccines.
Moderna
MRNA
Mkt Cap10.61B
Moderna is involved in mRNA-based vaccines, competing in the innovative vaccine technology space where Vaxil Bio operates.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech competes in the development of novel vaccines for a wide range of infectious diseases, aligning with Vaxil Bio's goals.
Pfizer
PFE
Mkt Cap140.15B
Pfizer develops and markets vaccines and therapeutics, directly competing with Vaxil Bio's vaccine development efforts.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its Janssen Pharmaceuticals division, develops vaccines, making it a competitor in the vaccine market.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline is a large pharmaceutical company with a significant vaccine portfolio, competing in the same market as Vaxil Bio.
Sanofi
SNY
Mkt Cap124.45B
Sanofi operates in the vaccine development space, making it a direct competitor to Vaxil Bio in the quest for innovative vaccines.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca is involved in the development and distribution of vaccines, competing with Vaxil Bio's vaccine development projects.
Inovio Pharmaceuticals
INO
Mkt Cap124.89M
Inovio Pharmaceuticals focuses on DNA-based vaccine development, competing with Vaxil Bio in the area of novel vaccine technologies.

About

Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. Its lead product candidate is ImMucin, a MUC1 SP-based vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. The company is headquartered in Toronto, Canada.
Show more...
CEO
Mr. Gadi Levin B.Com., C.A., CPA, M.B.A.
Country
CA
ISIN
CA92243L2066

Listings

OTC Link
US
VXLLF
V
CA
VXL.V

0 Comments

Share your thoughts

FAQ

What is Vaxil Bio stock price today?▼
The current price of VXLLF is $0.11 USD — it has increased by +4.76% in the past 24 hours. Watch Vaxil Bio stock price performance more closely on the chart.
What is Vaxil Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Vaxil Bio stocks are traded under the ticker VXLLF.
What is Vaxil Bio market cap?▼
Today Vaxil Bio has the market capitalization of 301,290
What were Vaxil Bio earnings last quarter?▼
VXLLF earnings for the last quarter are -0 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Vaxil Bio revenue for the last year?▼
Vaxil Bio revenue for the last year amounts to 0 USD.
What is Vaxil Bio net income for the last year?▼
VXLLF net income for the last year is -253,990.06 USD.
In which sector is Vaxil Bio located?▼
Vaxil Bio operates in the Health Care sector.
When did Vaxil Bio complete a stock split?▼
The last stock split for Vaxil Bio was on May 15, 2025 with a ratio of 1:50.
Where is Vaxil Bio headquartered?▼
Vaxil Bio is headquartered in Toronto, CA.